Nasus Pharma Ltd. (NSRX)
IL — Healthcare Sector
Automate Your Wheel Strategy on NSRX
With Tiblio's Option Bot, you can configure your own wheel strategy including NSRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NSRX
- Rev/Share 0.0
- Book/Share 0.0
- PB 0.0
- Debt/Equity 0.0
- CurrentRatio 0.0
- ROIC 0.0
- MktCap 59889617.0
- FreeCF/Share 0.0
- PFCF 0.0
- PE -39.0924
- Debt/Assets 0.0
- DivYield 0
- ROE 0.0
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed
NSRX
Published: November 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: November 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
The Phase 2 study is designed to address regulatory approval considerations by comparing bioavailability and pharmacokinetics of NS002 against EpiPen
Read More
About Nasus Pharma Ltd. (NSRX)
- IPO Date 2025-08-13
- Website http://www.nasuspharma.com
- Industry Biotechnology
- CEO Dan Teleman
- Employees 2
Nasus Pharma is a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical conditions such as severe allergies, anaphylaxis, and opioid overdose. Their lead products include NS002, an intranasal powder epinephrine nasal spray for type 1 severe allergies and anaphylaxis, and NS001, an intranasal naloxone powder spray for opioid overdose. They use a powder-based intranasal technology that offers rapid drug absorption.